This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Afargan, M. Articles by Oberg, K. Search for Related Content PubMed PubMed Citation Articles by Afargan, M. Articles by Oberg, K.

Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin

Departments of Medicinal Sciences and Endocrine Oncology (E.T.J., K.O.), University Hospital SE 75185, Uppsala, Sweden; Department of Organic Chemistry, Faculty of Life Sciences (C.G.), and Department of Pharmaceutical Sciences, School of Pharmacy, Faculty of Medicine (A.H., D.H.), Hebrew University, Jerusalem 91904, Israel; Department of Pharmacology, Medical School, University of Crete (G.L.), Heraklion, Crete 71110, Greece; and Peptor Ltd., Kiryat Weizmann (M.A., G.G., R.R., O.Z., O.K., M.B., D.S.), Rehovot 76326, Israel

Address all correspondence and requests for reprints to: Dr. Michel Afargan, Department of Pharmacology, Peptor Ltd., Kiryat Weizmann, Rehovot 76326, Israel. E-mail: hpbm{at}netvision.net.il

Somatostatin, also known as somatotropin release-inhibiting factor (SRIF), is a natural cyclic peptide inhibitor of pituitary, pancreatic, and gastrointestinal secretion. Its long-acting analogs are in clinical use for treatment of various endocrine syndromes and gastrointestinal anomalies. These analogs are more potent inhibitors of the endocrine release of GH, glucagon, and insulin than the native SRIF; hence, they do not display considerable physiological selectivity. Our goal was to design effective and physiologically selective SRIF analogs with potential therapeutic value. We employed an integrated approach consisting of screening of backbone cyclic peptide libraries constructed on the basis of molecular modeling of known SRIF agonists and of high throughput receptor binding assays with each of the five cloned human SRIF receptors (hsst1–5). By using this approach, we identified a novel, high affinity, enzymatically stable, and long-acting SRIF analog, PTR-3173, which binds with nanomolar affinity to human SRIF receptors hsst2, hsst4, and hsst5. The hsst5 and the rat sst5 (rsst5) forms have the same nanomolar affinity for this analog. In the human carcinoid-derived cell line BON-1, PTR-3173 inhibits forskolin-stimulated cAMP accumulation as efficiently as the drug octreotide, indicating its agonistic effect in this human cell system. In hormone secretion studies with rats, we found that PTR-3173 is 1000-fold and more than 10,000-fold more potent in inhibiting GH release than glucagon and insulin release, respectively. These results suggest that PTR-3173 is the first highly selective somatostatinergic analog for the in vivo inhibition of GH secretion, with minimal or no effect on glucagon and insulin release, respectively.

This article has been cited by other articles:

				F. P. Leu, M. Nandi, and C. Niu The Effect of Transforming Growth Factor {beta} on Human Neuroendocrine Tumor BON Cell Proliferation and Differentiation Is Mediated through Somatostatin Signaling Mol. Cancer Res., June 1, 2008; 6(6): 1029 - 1042. [Abstract] [Full Text] [PDF]

				Y. Segev, R. Eshet, I. Rivkis, C. Hayat, L. Kachko, M. Phillip, and D. Landau Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3021 - 3028. [Abstract] [Full Text] [PDF]

				S.-G. Ren, J. Taylor, J. Dong, R. Yu, M. D. Culler, and S. Melmed Functional Association of Somatostatin Receptor Subtypes 2 and 5 in Inhibiting Human Growth Hormone Secretion J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4239 - 4245. [Abstract] [Full Text] [PDF]